Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ST3GAL1 shRNA
- Development stage
- Preclinical
- Lead developer
- Albert Einstein College of Medicine
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal
01
Overview
ST3GAL1 shRNA is a short hairpin RNA (shRNA) designed to silence the expression of the ST3GAL1 gene, which encodes alpha-2,3-sialyltransferase 1. ST3GAL1 is a glycosyltransferase that mediates the alpha-2,3-sialylation of glycoproteins, a process found to be essential for melanoma maintenance and survival. By suppressing ST3GAL1, the shRNA inhibits the sialylation of transmembrane proteins such as the amino acid transporter CD98hc (SLC3A2), leading to reduced protein stability and subsequent inhibition of melanoma cell proliferation. This research-stage tool was identified through in vivo functional screens and supports ST3GAL1 as a novel therapeutic target in melanoma.
- Other names
- ST3GAL1 silencing RNAST-3GAL1 silencing RNAST 3GAL1 silencing RNAshRNA targeting ST3GAL1
02
Targets
ST (ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4)
Beyond the preview
Go deeper on ST3GAL1 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ST3GAL1 shRNA.